Amneal Pharmaceuticals (AMRX)
(Delayed Data from NSDQ)
$8.59 USD
-0.11 (-1.26%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $8.58 -0.01 (-0.12%) 6:54 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.59 USD
-0.11 (-1.26%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $8.58 -0.01 (-0.12%) 6:54 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
Zacks News
Amneal Pharmaceuticals (AMRX) Beats Q4 Earnings Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of 100% and 2.17%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Countdown to Amneal (AMRX) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Amneal (AMRX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.
Amneal (AMRX) Shows Fast-paced Momentum But Is Still a Bargain Stock
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Amneal (AMRX) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Aquestive Therapeutics (AQST) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.
Amneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Jazz Pharmaceuticals (JAZZ) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
United Therapeutics (UTHR) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
United Therapeutics (UTHR) delivered earnings and revenue surprises of 10.02% and 5.71%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Amneal Pharmaceuticals (AMRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amneal (AMRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Amneal (AMRX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Amneal (AMRX) Upgraded to Buy: Here's Why
by Zacks Equity Research
Amneal (AMRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year?
by Zacks Equity Research
Here is how Amneal Pharmaceuticals (AMRX) and KalVista Pharmaceuticals, Inc. (KALV) have performed compared to their sector so far this year.
Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here Is Why Bargain Hunters Would Love Fast-paced Mover Amneal (AMRX)
by Zacks Equity Research
Amneal (AMRX) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Is Haemonetics (HAE) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Haemonetics (HAE) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.
Amneal (AMRX) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Amneal (AMRX) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Amneal Pharmaceuticals (AMRX) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of 90% and 6.50%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Biotech Stock Roundup: BMRN's Gene Therapy Gets Approval, SGTX Up on Buyout by LLY
by Zacks Equity Research
Regulatory and acquisition updates from BioMarin (BMRN) and Sigilon (SGTX) are in focus in the biotech sector.
Amneal (AMRX) Shares Down on CRL for Parkinson's Disease Drug
by Zacks Equity Research
Amneal (AMRX) suffers a setback as the FDA issues a complete response letter (CRL) to its new drug application (NDA) for IPX203 for treating Parkinson's disease.
Earnings Preview: Theravance Biopharma (TBPH) Q1 Earnings Expected to Decline
by Zacks Equity Research
Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Amneal Pharmaceuticals (AMRX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amneal Pharmaceuticals (AMRX) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of 9.52% and 4.91%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
FDA Accepts Amneal's (AMRX) Parkinson's Candidate NDA For Review
by Zacks Equity Research
Amneal Pharmaceuticals' (AMRX) shares rise after the company announces that its Parkinson's candidate IPX203 NDA has been accepted for review by the FDA.
Amneal Pharmaceuticals (AMRX) Q3 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of -22.22% and 3.37%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Select Medical (SEM) Q3 Earnings Miss Estimates
by Zacks Equity Research
Select Medical (SEM) delivered earnings and revenue surprises of -52.27% and 1.14%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?